Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Address

345 PARK AVENUE SOUTH
NEW YORK, NY 10010

Founded

2017

Number of Employees

58

Website

http://www.lexeotx.com

Buyback

Buyback Data 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
$ Amount Purchased
($ in 000s )		 - - - - - - - - - - $13 $13
Average Price - - - - - - - - - - $4.36 $4.36
# Shares Purchased - - - - - - - - - - 2,991 2,991
Buyback Performance 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
Total Return to Date - - - - - - - - - - 106.4% 106.4%
S&P 500 Return to Date - - - - - - - - - - 7.4% 7.4%
Excess Total Return - - - - - - - - - - 99.0% 99.0%
Quartile Rank
Percentile Rank - - - - - - - - - - 99% 85%
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed
LONGITUDE VENTURE PARTNERS IV, L.P.

Eargo, Inc.
AGGER METTE KIRSTINE

scPharmaceuticals Inc.
ROBERTSON JENNY

Lexeo Therapeutics, Inc.
ENRIGHT PATRICK G

COLLEGIUM PHARMACEUTICAL, INC